JP2023113650A5 - - Google Patents

Download PDF

Info

Publication number
JP2023113650A5
JP2023113650A5 JP2023077882A JP2023077882A JP2023113650A5 JP 2023113650 A5 JP2023113650 A5 JP 2023113650A5 JP 2023077882 A JP2023077882 A JP 2023077882A JP 2023077882 A JP2023077882 A JP 2023077882A JP 2023113650 A5 JP2023113650 A5 JP 2023113650A5
Authority
JP
Japan
Prior art keywords
erdafitinib
composition
serum phosphate
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023077882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023113650A (ja
Filing date
Publication date
Priority claimed from JP2019566178A external-priority patent/JP2020521794A/ja
Application filed filed Critical
Publication of JP2023113650A publication Critical patent/JP2023113650A/ja
Publication of JP2023113650A5 publication Critical patent/JP2023113650A5/ja
Pending legal-status Critical Current

Links

JP2023077882A 2017-06-02 2023-05-10 胆管癌の治療のためのfgfr2阻害剤 Pending JP2023113650A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17174295.0 2017-06-02
EP17174295 2017-06-02
EP18171315.7 2018-05-08
EP18171315 2018-05-08
JP2019566178A JP2020521794A (ja) 2017-06-02 2018-06-01 胆管癌の治療のためのfgfr2阻害剤
PCT/EP2018/064523 WO2018220206A1 (en) 2017-06-02 2018-06-01 Fgfr2 inhibitors for the treatment of cholangiocarcinoma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019566178A Division JP2020521794A (ja) 2017-06-02 2018-06-01 胆管癌の治療のためのfgfr2阻害剤

Publications (2)

Publication Number Publication Date
JP2023113650A JP2023113650A (ja) 2023-08-16
JP2023113650A5 true JP2023113650A5 (cg-RX-API-DMAC7.html) 2024-02-16

Family

ID=62555054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566178A Withdrawn JP2020521794A (ja) 2017-06-02 2018-06-01 胆管癌の治療のためのfgfr2阻害剤
JP2023077882A Pending JP2023113650A (ja) 2017-06-02 2023-05-10 胆管癌の治療のためのfgfr2阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019566178A Withdrawn JP2020521794A (ja) 2017-06-02 2018-06-01 胆管癌の治療のためのfgfr2阻害剤

Country Status (16)

Country Link
US (2) US11707463B2 (cg-RX-API-DMAC7.html)
EP (1) EP3634414A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020521794A (cg-RX-API-DMAC7.html)
KR (1) KR20200010505A (cg-RX-API-DMAC7.html)
CN (1) CN111050769A (cg-RX-API-DMAC7.html)
AU (1) AU2018278271B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019025056A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064317A1 (cg-RX-API-DMAC7.html)
IL (1) IL271058A (cg-RX-API-DMAC7.html)
JO (1) JOP20190280A1 (cg-RX-API-DMAC7.html)
MA (1) MA49248A (cg-RX-API-DMAC7.html)
MX (1) MX2019014366A (cg-RX-API-DMAC7.html)
MY (1) MY204203A (cg-RX-API-DMAC7.html)
PH (1) PH12019502710A1 (cg-RX-API-DMAC7.html)
UA (1) UA126478C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018220206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
BR112021015686A2 (pt) * 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
MX2021011926A (es) * 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
CA3141869A1 (en) * 2019-05-28 2020-12-03 Qed Therapeutics, Inc. Methods of treating cholangiocarcinoma
TW202114665A (zh) * 2019-08-05 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯并六員雜環化合物在製備治療fgfr2基因變異的腫瘤的藥物中的用途
WO2021146163A1 (en) * 2020-01-17 2021-07-22 Beta Pharma, Inc. Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
WO2008118877A2 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CA2898326C (en) * 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Similar Documents

Publication Publication Date Title
Rashad et al. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer
JP2020505425A5 (cg-RX-API-DMAC7.html)
JP2020521794A5 (cg-RX-API-DMAC7.html)
Farrand et al. Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson’s disease model
Dresner et al. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia
Suzuki et al. Sustained-release lidocaine sheet for pain following tooth extraction: A randomized, single-blind, dose-response, controlled, clinical study of efficacy and safety
CN109966329A (zh) 一种梅花草提取物在治疗急性咽炎中的应用
McElroy et al. Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania
JP2023513298A5 (cg-RX-API-DMAC7.html)
Frass et al. Two cases of fulminant hepatic failure from amanita phalloides poisoning treated additively by homeopathy
Thomas et al. Neurological manifestations in chronic mountain sickness: the burning feet-burning hands syndrome
Pasloske et al. The bioequivalence of a single intravenous administration of the anesthetic alfaxalone in cyclodextrin versus alfaxalone in cyclodextrin plus preservatives in cats
Kang et al. Reversal with sugammadex for rocuronium-induced deep neuromuscular block after pretreatment of magnesium sulfate in rabbits
JP3916563B2 (ja) P物質の投与を含む治療方法
Djabir The protective effect of Paliasa (Kleinhovia hospita L.) leaf extract against elevated total bilirubin serum induced by toxic dose of antituberculosis in rats
CA3177260A1 (en) Endoxifen for the treatment of bipolar i disorder
CN1083357A (zh) 治疗风湿病的药
RU2201179C2 (ru) Способ лечения диабетических ретинопатий
WO1996040038A2 (en) Treatment of anemia with procaine compositions
JP2022501355A5 (cg-RX-API-DMAC7.html)
CA3177266A1 (en) Endoxifen for the treatment of bipolar i disorder
Apter et al. Lithium augmentation of bupropion in refractory depression
Bhandari et al. Gabapentin pre-treatment for pressor response to direct laryngoscopy and tracheal intubation: a randomized, doubleblind, placebo controlled study
JP2024535467A5 (cg-RX-API-DMAC7.html)
Chen et al. Effect of cyclosporine‐A on orthodontic tooth movement in rats